Last updated: February 19, 2026
This report analyzes New Zealand patent NZ568179, detailing its scope, claims, and the surrounding patent landscape relevant to its therapeutic area. The patent, filed by Merck Sharp & Dohme (MSD) on September 24, 2007, and granted on April 24, 2014, pertains to methods of treating certain medical conditions using specific pharmaceutical compositions. The granted term extends to September 24, 2027.
What is the Core Invention Protected by NZ568179?
The central innovation covered by NZ568179 relates to the treatment of metabolic syndrome. Specifically, the patent claims methods for reducing the risk of developing type 2 diabetes in individuals who have been diagnosed with metabolic syndrome. The claimed treatment involves administering a pharmaceutical composition containing a specific active pharmaceutical ingredient.
What are the Key Claims of NZ568179?
The patent contains several claims, with Claim 1 being the most fundamental.
Claim 1: This claim defines a method for reducing the risk of developing type 2 diabetes in a subject diagnosed with metabolic syndrome. The method requires administering to the subject a pharmaceutical composition that includes a therapeutically effective amount of sitagliptin or a pharmaceutically acceptable salt thereof. The claimed composition is designed for once-daily administration.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It functions by increasing the levels of incretin hormones, which play a role in regulating blood glucose levels. By inhibiting DPP-4, sitagliptin enhances the body's own ability to lower blood sugar after meals.
The patent specifies that the subject has been diagnosed with metabolic syndrome. Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and type 2 diabetes. These conditions include high blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels.
The emphasis on "once-daily administration" suggests a focus on patient compliance and therapeutic convenience, which are critical factors in chronic disease management.
Other claims within the patent typically cover:
- Specific dosages of sitagliptin: These claims may define particular dose ranges or specific amounts of sitagliptin to be administered.
- Compositions with specific excipients: Claims might detail formulations that include particular inactive ingredients (excipients) designed to enhance the stability, bioavailability, or delivery of sitagliptin.
- Subgroups of patients: The patent could also claim methods for specific sub-populations within the metabolic syndrome group, based on particular biomarkers or disease characteristics.
- Combination therapies: While not explicitly detailed in the summary of Claim 1, related claims could potentially cover the co-administration of sitagliptin with other therapeutic agents.
The precise wording and scope of these dependent claims are crucial for determining the exact breadth of protection afforded by the patent. A thorough review of the full patent document is necessary for complete understanding.
What is the Therapeutic Area and Target Indication?
The therapeutic area addressed by NZ568179 is endocrinology, specifically focusing on metabolic disorders and diabetes prevention.
The target indication is metabolic syndrome, with the ultimate goal of reducing the risk of developing type 2 diabetes. This is a significant area of unmet medical need, as individuals with metabolic syndrome have a substantially elevated risk of progressing to type 2 diabetes. Early intervention to prevent or delay this progression is a key objective in diabetes care.
Sitagliptin, the active ingredient, is known for its use in treating existing type 2 diabetes. However, NZ568179 specifically claims its use in a pre-diabetic state for risk reduction, highlighting a potential expanded indication and a proactive approach to diabetes management.
What is the Global Patent Landscape for Sitagliptin and Related Therapies?
The patent landscape for sitagliptin is extensive, reflecting its commercial significance as a blockbuster drug. Merck & Co., Inc. (MSD's parent company) has secured broad patent protection globally for sitagliptin and its various uses.
Key Patents and Their Status:
- Composition of Matter Patents: The original patents covering the sitagliptin molecule itself have generally expired in major markets, including the United States and Europe. For example, the foundational US patent for sitagliptin expired in 2022. However, the expiration of composition of matter patents opens the door for generic competition.
- Method of Use Patents: Patents like NZ568179 are method of use patents. These patents claim specific therapeutic applications or methods of treatment. Even after the composition of matter patent expires, method of use patents can provide extended market exclusivity for a particular indication. This is the primary mechanism through which NZ568179 offers protection in New Zealand.
- Formulation Patents: Patents covering specific pharmaceutical formulations of sitagliptin, such as extended-release versions or fixed-dose combinations with other drugs, can also extend market exclusivity. For instance, sitagliptin is often formulated in combination with metformin.
Timeline of Sitagliptin's Commercialization and Patent Expiries:
| Event |
Date |
Notes |
| US Patent Application Filed |
2003 |
Original filings for sitagliptin. |
| US Patent Granted (Composition) |
2005 |
Key patent protecting the sitagliptin molecule. |
| FDA Approval (Januvia) |
2006 |
First approval for treatment of type 2 diabetes. |
| US Patent Expiration (Composition) |
2022 |
Major markets' composition patents have expired or are expiring. |
| NZ568179 Filing |
Sept 2007 |
Filed in New Zealand, focusing on metabolic syndrome to reduce type 2 diabetes risk. |
| NZ568179 Grant |
April 2014 |
Patent granted in New Zealand. |
| NZ568179 Expiration (Estimated) |
Sept 2027 |
Based on filing date and standard patent term. |
Global Patent Status: While core composition patents have largely expired, the strategic filing and granting of method of use patents like NZ568179 are critical for maintaining market exclusivity for specific therapeutic applications. This patent's expiration in September 2027 in New Zealand means that generic sitagliptin for the treatment of metabolic syndrome to reduce type 2 diabetes risk can potentially enter the market in New Zealand after this date, provided no other overlapping patents exist for that specific use.
How Does NZ568179 Relate to Other Sitagliptin Patents?
NZ568179 is a method of use patent that complements earlier composition of matter patents for sitagliptin. While the molecule itself may be off-patent in many jurisdictions, the specific application claimed in NZ568179 — the reduction of type 2 diabetes risk in patients with metabolic syndrome via once-daily administration of sitagliptin — is protected in New Zealand until September 2027.
This means that even if generic sitagliptin is available for treating diagnosed type 2 diabetes, its use for the specific preventative indication covered by NZ568179 remains under patent protection within New Zealand. Pharmaceutical companies seeking to market sitagliptin for this specific indication in New Zealand would need to navigate this patent's claims.
This strategy is common in the pharmaceutical industry: companies secure patents on the core molecule and then file further patents on novel uses, formulations, or delivery methods to extend market exclusivity beyond the original patent's lifespan.
What are the Implications of NZ568179 for Market Entry?
The existence of NZ568179 has several implications for market entry and competition in New Zealand, particularly for generic manufacturers or companies developing alternative therapies for metabolic syndrome and type 2 diabetes prevention.
- Restriction on Specific Indication: For any entity wishing to market sitagliptin in New Zealand for the specific purpose of reducing the risk of type 2 diabetes in individuals with metabolic syndrome, NZ568179 presents a barrier to entry until its expiration. Generic sitagliptin manufacturers can produce and sell the drug for other approved indications (e.g., treatment of type 2 diabetes, if approved and off-patent for that use), but they cannot market it for the use claimed by NZ568179 without infringing the patent.
- Dated Market Exclusivity: The patent grants MSD a period of exclusivity for this specific therapeutic application until September 2027. This allows MSD to maintain market share and pricing power for this indication without direct competition in New Zealand.
- Potential for Litigation: Companies intending to enter the market with sitagliptin for this indication post-patent expiration may face scrutiny or potential patent litigation if the claims are perceived to be infringed.
- Focus on Off-Patent Uses: Generic companies may focus on marketing sitagliptin for indications where the patent protection has expired or is weaker, or for which regulatory approvals for those uses are already established and less restrictive.
- Development of Alternative Therapies: The existence of such patents can incentivize the development of new therapeutic agents or strategies for managing metabolic syndrome and preventing type 2 diabetes that do not fall under the scope of NZ568179. This might include novel drug classes, lifestyle interventions, or combination therapies.
What are the Regulatory Considerations in New Zealand?
In New Zealand, the Intellectual Property Office of New Zealand (IPONZ) administers the patent system. Once a patent is granted, it provides exclusive rights to the patent holder.
- Patent Enforcement: The patent holder, MSD, has the right to take legal action against any party found to be infringing its patent. This typically involves injunctions to prevent further infringement and potentially damages for past infringement.
- Generic Approval Process: The Medicines and Medical Devices Safety Authority (Medsafe) is responsible for the regulation of medicines in New Zealand. While Medsafe approves medicines based on safety, efficacy, and quality, it does not directly consider patent status in its approval decisions. However, a marketing authorization from Medsafe does not override existing patent rights.
- Patent Linkage: New Zealand does not have a formal patent linkage system like the U.S. Food and Drug Administration (FDA), where generic drug approval is automatically tied to patent certifications. However, generic companies must be mindful of existing patents when launching their products to avoid infringement. They may seek a "no-challenge" opinion or prepare for potential litigation.
- Data Exclusivity: In addition to patent protection, New Zealand offers data exclusivity for certain new drug applications, which can provide an additional period of market protection even if the core patent has expired. The duration and specifics of data exclusivity are governed by the New Zealand Pharmaceutical and Related Industries Association (NZPIRA) code and relevant regulations. However, this patent relates to a method of use for an already approved drug, so data exclusivity typically applies to new active ingredients or novel formulations for which new clinical trial data is submitted.
Key Takeaways
- New Zealand patent NZ568179 grants Merck Sharp & Dohme (MSD) exclusive rights until September 2027 for methods of reducing the risk of type 2 diabetes in individuals with metabolic syndrome using once-daily sitagliptin.
- The patent protects a specific method of use, distinct from earlier composition of matter patents for sitagliptin which have generally expired in major markets.
- This patent creates a temporary barrier for generic manufacturers and competing therapies aiming to address this specific preventative indication in New Zealand.
- Market entry for sitagliptin for this particular use in New Zealand is restricted until the patent's expiration on September 24, 2027.
- Regulatory approval from Medsafe does not confer the right to infringe upon valid patent protections.
Frequently Asked Questions
-
When will NZ568179 expire?
NZ568179 is expected to expire on September 24, 2027.
-
Does NZ568179 cover the use of sitagliptin for treating type 2 diabetes?
While sitagliptin is used to treat type 2 diabetes, NZ568179 specifically claims the method of reducing the risk of developing type 2 diabetes in individuals diagnosed with metabolic syndrome. Its claims are narrower than general type 2 diabetes treatment.
-
Can generic sitagliptin be sold in New Zealand before September 2027?
Generic sitagliptin can be sold in New Zealand before September 2027 for uses not covered by NZ568179 or other relevant patents. However, marketing it for the specific indication claimed by NZ568179 would constitute patent infringement.
-
What is "metabolic syndrome" in the context of this patent?
Metabolic syndrome is a cluster of conditions including high blood pressure, high blood sugar, excess abdominal fat, and abnormal cholesterol or triglyceride levels, which collectively increase the risk of heart disease, stroke, and type 2 diabetes.
-
Does this patent prevent the development of new drugs for metabolic syndrome in New Zealand?
NZ568179 does not prevent the development of new drugs for metabolic syndrome. It specifically protects the method of using sitagliptin for a defined preventative purpose. New therapeutic agents would be subject to their own patent applications and regulatory reviews.
Citations
[1] Merck Sharp & Dohme. (2007). Pharmaceutical composition containing sitagliptin or a pharmaceutically acceptable salt thereof. New Zealand Patent Application No. 568179.
[2] Intellectual Property Office of New Zealand. (n.d.). Patent Search. Retrieved from https://www.iponz.govt.nz/
[3] U.S. Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-databases
[4] Medicines and Medical Devices Safety Authority (Medsafe). (n.d.). Medsafe Website. Retrieved from https://www.medsafe.govt.nz/
